Please login to the form below

Not currently logged in
Email:
Password:

MedImmune partners with university on protein formulation science

Four-year partnership to research antibodies and novel proteins
MedImmune office

MedImmune has added to its list of research collaborations by partnering with the University of Manchester on protein formulation science.

As part of the collaboration, MedImmune, the biologics arm of AstraZeneca, will work with researchers at Manchester's Centre of Excellence on Biopharmaceuticals (COEBP) on understanding protein solution behaviour in order to discover better ways to administer medicines to patients.

Gail Wasserman, senior VP of biopharmaceutical development at MedImmune, commented: “Through this collaboration, we hope to deepen our knowledge of the underlying protein formulation science and increase our capability to deliver formulations that will help transform the best protein molecules into the best potential treatments for patients.”

The four-year partnership will enhance research supporting new formulation approaches for antibodies and novel proteins, with funding provided by MedImmune. 

The firm will additionally supply support for several of the university's post-doctoral research projects looking into challenges caused in protein antibody formulation, such as the importance of ultra-high concentration liquid formulations and room temperature stable products.

Head of the COEBP at the University of Manchester Professor Alan Dickson said: “We look forward to working with MedImmune to generate exciting breakthrough science together in this important research field. 

“Our collaboration will form a distinct, vibrant scientific community, with the aim to formulate products more intelligently and innovatively and ensure accelerated development of key medicines.”

The announcement comes just weeks after MedImmune revealed a new partnership with the US National Center Institute (NCI), which will include investigative studies into its PD-1 candidate MEDI4736 in combination with other treatments.

Article by
Kirstie Pickering

9th February 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics